Overweight Subject
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin (NCT07331389) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-09-24 |
| A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. (NCT06601517) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-10-01 |
Track Overweight Subject automatically
Every clearance here is in the API, with alerts when new ones post.